Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Signs Two Deals for MicroRNA Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced two collaborations to advance its microRNA-based diagnostic tests.

The Rehovot, Israel-based company has signed agreements with Tel Hashomer Medical Research Infrastructure and Services and Carmel Medical Center, both also based in Israel, to develop and validate Rosetta's miRNA-based tests for indications related to its Gen 3 products.

The Gen 3 tests will focus on cardiovascular disease, neurodegenerative disease, women's health, and early detection of certain cancers. They are designed to leverage miRNA biomarkers found in body fluids, Rosetta said.

Financial and other terms of the deal were not disclosed.

"Our goal is to obtain proof-of-concept data on at least one of our Gen 3 products this year," Kenneth Berlin, president and CEO of Rosetta, said in a statement. "With encouraging preliminary data in two of these Gen 3 indications already, Rosetta will be conducting studies to determine if these results hold up over larger sample sizes."

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.